|
2024
|
Invention
|
Egfr inhibitor for treating cancers comprising atypical egfr mutations. The present application p... |
|
|
Invention
|
Treatment of t-cell lymphoma. Disclosed herein are methods of treating T-cell lymphoma in a subje... |
|
|
Invention
|
Treatment of neuroendocrine prostate cancer. Disclosed herein are methods of treating neuroendocr... |
|
2023
|
Invention
|
Treatment of prostate cancer having androgen receptor variants. Disclosed herein are methods of t... |
|
|
Invention
|
Malonate and glycolate salts of an egfr inhibitor. The present application provides salts and cry... |
|
|
Invention
|
Polo like kinase 4 inhibitors. Disclosed herein are compounds of Formula (IV), or pharmaceuticall... |
|
|
Invention
|
Cd73 inhibitors.
Described herein are CD73 inhibitors and pharmaceutical compositions comprising... |
|
|
Invention
|
Physical forms of an inhibitor of prc2. The present disclosure relates to physical forms of a PRC... |
|
|
Invention
|
Pharmaceutical forms of a cd73 inhibitor. The present disclosure relates to pharmaceutical forms ... |
|
|
Invention
|
Polo like kinase 4 inhibitors. Disclosed herein are compounds of Formula (I), or pharmaceutically... |
|
|
G/S
|
Pharmaceutical preparations for use in the treatment of cancer, tumors, and hematological maligna... |
|
2022
|
Invention
|
Cd73 inhibitors. Described herein are CD73 inhibitors and pharmaceutical compositions comprising ... |
|
|
Invention
|
Inhibitors of epidermal growth factor receptor. Disclosed herein are compounds of Formula (I), or... |
|
|
Invention
|
Prc2 inhibitors for use in treating blood disorders.
The present disclosure relates to methods o... |
|
|
Invention
|
Prc2 inhibitors for use in treating blood disorders. The present disclosure relates to methods of... |
|
|
Invention
|
Inhibitors of glucocorticoid receptor.
The present invention relates generally to compositions a... |
|
|
G/S
|
pharmaceutical preparations for use in the treatment of cancer, tumors, and hematological maligna... |
|
|
Invention
|
Polo like kinase 4 inhibitors.
Disclosed herein are compounds of Formula (I), or pharmaceuticall... |
|
|
Invention
|
Uses of glucocorticoid receptor (gr) antagonist, antiandrogen, and akt inhibitor/pi3k inhibitor/m... |
|
2021
|
Invention
|
Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations.... |
|
|
G/S
|
drugs for addressing medical conditions, namely, medicinal preparations for treating cancers or t... |
|
|
Invention
|
Glucocorticoid receptor gene signature. The present invention relates generally to the use of a p... |
|
|
G/S
|
Pharmaceutical preparations and substances; pharmaceutical preparations for use in the treatment ... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the trea... |
|
|
Invention
|
Uses of glucocorticoid receptor antagonists. The present invention relates generally to the use o... |
|
2019
|
Invention
|
Glucocorticoid receptor modulators.
Described herein are glucocorticoid receptor modulators and ... |
|
|
Invention
|
Glucocorticoid receptor modulators. Described herein are glucocorticoid receptor modulators and p... |
|
|
Invention
|
Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof.
T... |
|
2016
|
Invention
|
Inhibitors of glucocorticoid receptor. The present invention relates generally to compositions an... |
